Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 3;8(8):567–576. doi: 10.1002/psp4.12411

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Study workflow. In a first step, physiologically‐based pharmacokinetic (PBPK) models for substrates and inhibitors were built, optimized, or used unchanged from verified library compounds in Simcyp version 17. In a second step, the Cytochrome P450 2D6 (CYP2D6) genotype‐dependent CYP2D6‐mediated clearance of substrate and inhibitors were estimated from existing in vivo data in humans. Then the third step consisted in the simulations of genotype‐dependent drug–drug interactions (DDIs) to compare with existing DDI trials.